Accueil

Actualités réglementaires

Évolutions réglementaires FDA, EMA, TGA et mondiales

#generic drugs ×

UPDATED
Actualités réglementaires
27 sept. 2026•1 min de lecture
FDA Approves ANDA077302 for Actavis Extended‑Release Amphetamine Combination Capsules
The FDA approved ANDA077302 for Actavis Pharma’s oral extended‑release capsules containing dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate in multiple strengths.
UPDATED
Actualités réglementaires
27 sept. 2026•1 min de lecture
FDA Approves ANDA077013 for Pravastatin Sodium Tablets by Pharmobedient
The FDA has approved application ANDA077013 for pravastatin sodium tablets (10‑80 mg) from sponsor Pharmobedient; all listed product numbers are marked discontinued.
UPDATED
Actualités réglementaires
25 sept. 2026•1 min de lecture
FDA Approves Manufacturing Supplements for Isoniazid (ANDA080132)
FDA approved three manufacturing supplement submissions for Isoniazid tablets (50 mg and 100 mg) under ANDA080132; both products are listed as discontinued.
UPDATED
Actualités réglementaires
24 sept. 2026•1 min de lecture
FDA Approves ANDA211623 for Generic Carbamazepine Extended‑Release Tablets
The FDA has approved ANDA211623 for carbamazepine extended‑release tablets (100 mg, 200 mg, 400 mg) submitted by Unique Pharm, with labeling cleared in Jan 2024.
UPDATED
Actualités réglementaires
22 sept. 2026•1 min de lecture
FDA Approves Multiple Supplemental Applications for Discontinued Chlorothiazide Tablets (ANDA 084217)
The FDA record for ANDA 084217 lists two discontinued oral chlorothiazide tablets (500 mg and 250 mg) and a series of approved supplemental submissions covering manufacturing, labeling and bioequivalence.
UPDATED
Actualités réglementaires
19 sept. 2026•1 min de lecture
FDA Approves ANDA077345 for Sertraline Hydrochloride Tablets (Heritage Pharma Avet)
The FDA has approved ANDA077345 submitted by Heritage Pharma Avet for oral sertraline hydrochloride tablets in 25 mg, 50 mg and 100 mg strengths. All listed products are currently marked discontinued.
UPDATED
Actualités réglementaires
18 sept. 2026•1 min de lecture
FDA Grants ANDA Approval for Atomoxetine Capsules by Strides Pharma
The FDA approved ANDA 079021 for atomoxetine hydrochloride capsules from Strides Pharma Science, covering strengths from 10 mg to 100 mg.
1
UPDATED
Actualités réglementaires
18 sept. 2026•1 min de lecture
FDA Approves Zydus Lifesciences’ Generic Leflunomide Tablets (ANDA212308)
The FDA has granted approval for Zydus Lifesciences’ generic leflunomide tablets (10 mg and 20 mg) under ANDA212308.
UPDATED
Actualités réglementaires
14 sept. 2026•1 min de lecture
South Korea Introduces New Designation for Semi‑Innovative Pharma Firms with R&D‑Based Price Benefits
Korea's Ministry of Health and Welfare unveils a designation system granting generic price incentives to semi‑innovative pharma companies that meet R&D investment thresholds, excluding violations older than five years.
UPDATED
Actualités réglementaires
13 sept. 2026•1 min de lecture
FDA Approves Cipla Esomeprazole Magnesium ANDA078003
FDA granted approval for Cipla's ANDA078003 generic esomeprazole magnesium, covering two discontinued oral capsule products.
UPDATED
Actualités réglementaires
11 sept. 2026•1 min de lecture
FDA Grants ANDA Approval for PHARMASCIENCE INC (ANDA205757)
The FDA issued a standard review tentative approval (TA) for ANDA205757 submitted by Pharmascience Inc., status dated Feb 15, 2019.
UPDATED
Actualités réglementaires
9 sept. 2026•2 min de lecture
PMDA Hokuriku Branch Marks 10‑Year Anniversary with Regulatory Cooperation Symposium
The PMDA and Toyama Prefecture hosted a symposium celebrating the Hokuriku Branch’s 10th anniversary, highlighting regulatory training and collaboration across Asia.